<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Experimental evidence suggests that intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 mediated leukocyte extravasation contributes to the pathogenesis of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="9150">Simvastatin</z:chebi>, an <z:chebi fb="0" ids="35664">HMG-CoA reductase inhibitor</z:chebi>, decreases intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 expression and competitively inhibits leukocyte intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 binding </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that administration of <z:chebi fb="0" ids="9150">simvastatin</z:chebi> after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) would attenuate perivascular granulocyte migration and ameliorate <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in a rabbit model of SAH </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: New Zealand white rabbits (n = 15) underwent injection of autologous blood into the cisterna magna or sham surgery followed by subcutaneous injection of <z:chebi fb="0" ids="9150">simvastatin</z:chebi> (40 mg/kg) or vehicle 30 minutes, 24 hours, and 48 hours after SAH or sham surgery </plain></SENT>
<SENT sid="4" pm="."><plain>Seventy-two hours later, basilar artery lumen diameter was measured by in situ perfusion/fixation and image analysis </plain></SENT>
<SENT sid="5" pm="."><plain>CD-18 monoclonal antibody stained perivascular granulocytes and macrophages were counted under light microscopy </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In vehicle treated rabbits, mean +/- standard deviation basilar artery diameter was reduced 3 days after SAH (n = 5) versus sham (n = 5) rabbits (0.49 +/- 0.08 mm versus 0.75 +/- 0.03 mm, P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>After SAH, mean +/- standard deviation basilar artery diameter was greater in <z:chebi fb="0" ids="9150">simvastatin</z:chebi> (n = 5) treated rabbits versus vehicle (n = 5) (0.63 +/- 0.04 mm versus 0.49 +/- 0.08 mm, P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>In vehicle treated rabbits, SAH resulted in an increase in the mean +/- standard deviation perivascular CD18 cell count (sham-vehicle, 2.8 +/- 2; SAH-vehicle 90 +/- 27; P &lt; 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>Subcutaneous administration of <z:chebi fb="0" ids="9150">simvastatin</z:chebi> attenuated this increase in perivascular CD18-positive cells after SAH (SAH <z:chebi fb="0" ids="35664">statin</z:chebi>, 41.6 +/- 13; SAH vehicle, 90 +/- 27; P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Subcutaneous administration of <z:chebi fb="0" ids="9150">simvastatin</z:chebi> after the <z:hpo ids='HP_0003674'>onset</z:hpo> of SAH attenuates perivascular granulocyte migration and ameliorates basilar artery vasospasm after experimental SAH in rabbits </plain></SENT>
<SENT sid="11" pm="."><plain>5-hydroxy-3-methylglutaryl-<z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitors, such as <z:chebi fb="0" ids="9150">simvastatin</z:chebi>, may potentially serve as agents in the prevention of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after SAH </plain></SENT>
</text></document>